| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Upserve, originally Swipely, provides a restaurant management platform which allows independent full-service restaurants to run and manage their entire business.
With Identiqs truly anonymous verification network, members fight fraud and improve user experience by validating new users, and vouching for ones they already know, without sharing any personal user data at all.
CloudGenera is the solution that provides IT decisions as a service, with data-driven software providing recommendations.....
Qlipso is a New York, NY-based company in the Software & Internet sector.